Vasomedical EECP played a major role in pioneering External Counterpulsation Therapy worldwide. Vasomedical is most known for trademarking “EECP” which stands for “Enhanced” External Counterpulsation Therapy.
Vasomedical is a well-known name in External Counterpulsation Therapy because of their role in sponsoring more than 90% of all of the clinical studies performed. These trials have played a critical role demonstrating the viability of External Counterpulsation Therapy for Angina, Heart Failure and a vast array of other medical conditions. Vasomedical is the most recognized name of all the manufacturers around the world because they are the only company that can legally use “EECP” to describe External Counterpulsation Therapy. And since they sponsored virtually all of the Clinical work on External Counterpulsation Therapy, they have the most exposure.
To this day, our records here at ExternalCounterpulsation.com indicate that Vasomedical has sold more total machines (units) than any other U.S manufacturer. Vasomedical has made four main product models since reimbursement became available in the U.S. from Medicare in 1999. Vasomedical have a proven track record of reliability in their EECP devices particularly with the older model machines (MC-2, TS-3 models).
As a result of obtaining reimbursement from Medicare in 1999, Vasomedical enjoyed enormous success in system sales in the early 2000’s. The initial years of success were quite significant including going public on the U.S NASDAQ stock exchange in 2003. These early years of prosperity were marked by their initial public offering from the as well as little to no competition. It wasn’t until 2003-2004 until any real competitor entered the market.
Public funding enabled Vasomedical to continue to sponsor clinical trials for Congestive Heart Failure (PEECH) and many other studies in an effort to expand the application of External Counterpulsation Therapy.. As rumor has it, the lack of success with PEECH coupled with a significant increase in competition marked a reality check for Vasomedical. Sales slowed from compeition and a relative plateau in the market led Vasomedical into various restructuring arrangements including several changes in ownership. In 2007, Vasomedical sold a large portion of its stock (majority stock acquisition) to a U.S based Chinese company called Living Data Technology Corporation. Click Here for more information
Since that acquisition, Vasomedical has changed its product & distribution focus to continue its growth and satisfy shareholders. Vasomedical now offers other products in cardiology including Holter Monitoring systems, Ambulatory Blood Pressure and GE imaging products. Their operations consist of of three wholly owned subsidiaries.
Vasomedical EECP Systems
Vasomedical has introduced four different products since Medicare began providing reimbursement for External Counterpulsation Therapy in 1999.
- MC-2 EECP Therapy Device released in 1999.
- TS-3 EECP Therapy Device released in 2001
- TS-4 EECP Therapy Device released in 2003
- Lumenair EECP Therapy Device released in 2004
As a result of the Merger with Living Data, Vasomedical attempted to sell the two Chinese-based devices in the U.S. market. With virtually no success, Vasomedical reverted their efforts back to the U.S. based EECP product line with the Lumenair resulting in much better success.
For more details about each device, be sure to download the “Product Comparison” and visit “ECP & EECP® Product Reviews” to learn more details of Vasomedical EECP device features and how they compare to other devices in the industry.
Legal & Safety Notice
Vasomedical has an impeccable track record for manufacturing safe & reliable medical devices. The only report on record was a “FDA Warning” letter regarding safety rumored to be instigated by a competitor in the early 2000’s.